Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
AXDX

AXDX - Accelerate Diagnostics Inc Stock Price, Fair Value and News

1.11USD-0.02 (-1.77%)Market Closed

Market Summary

AXDX
USD1.11-0.02
Market Closed
-1.77%

AXDX Stock Price

View Fullscreen

AXDX RSI Chart

AXDX Valuation

Market Cap

24.5M

Price/Earnings (Trailing)

-0.41

Price/Sales (Trailing)

2.01

EV/EBITDA

-0.18

Price/Free Cashflow

-0.69

AXDX Price/Sales (Trailing)

AXDX Profitability

EBT Margin

-478.32%

Return on Equity

229.07%

Return on Assets

-192.22%

Free Cashflow Yield

-144.14%

AXDX Fundamentals

AXDX Revenue

Revenue (TTM)

12.2M

Rev. Growth (Yr)

3.88%

Rev. Growth (Qtr)

-3.5%

AXDX Earnings

Earnings (TTM)

-59.1M

Earnings Growth (Yr)

15.27%

Earnings Growth (Qtr)

-9.48%

Breaking Down AXDX Revenue

Last 7 days

-3.5%

Last 30 days

-4.3%

Last 90 days

29.1%

Trailing 12 Months

-83.4%

How does AXDX drawdown profile look like?

AXDX Financial Health

Current Ratio

1.5

AXDX Investor Care

Shares Dilution (1Y)

120.88%

Diluted EPS (TTM)

-4.21

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202412.2M000
202312.6M11.7M12.0M12.1M
202212.2M13.3M13.1M12.8M
202111.3M12.0M11.5M11.8M
20209.9M10.2M11.5M11.2M
20196.6M6.7M7.6M9.3M
20184.4M5.4M6.0M5.7M
2017613.0K1.3M2.1M4.2M
2016224.0K226.0K229.0K246.0K
2015122.0K127.0K132.0K75.0K
201446.0K52.0K55.0K122.0K
201380.0K41.0K48.2K48.0K
2012241.7K238.8K236.0K158.0K
201100244.5K243.1K
20100000

Tracking the Latest Insider Buys and Sells of Accelerate Diagnostics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 28, 2024
francesconi louise
acquired
-
-
4,737
-
Jun 28, 2024
massarany hany
acquired
-
-
4,737
-
Jun 28, 2024
schuler jack w
acquired
-
-
4,737
-
May 31, 2024
burris wayne
acquired
-
-
839
-
May 29, 2024
francesconi louise
acquired
-
-
7,894
-
May 29, 2024
massarany hany
acquired
-
-
7,894
-
May 29, 2024
regan jennifer
acquired
-
-
12,631
-
May 29, 2024
schuler jack w
acquired
-
-
7,894
-
May 20, 2024
schuler jack w
acquired
-
-
1,560,690
-
May 20, 2024
mertz larry michael
sold
-317
0.88
-361
chief technology officer

1–10 of 50

Which funds bought or sold AXDX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jul 19, 2024
Ironwood Financial, llc
added
10.09
5,906
25,521
0.01%
Jul 17, 2024
Householder Group Estate & Retirement Specialist, LLC
sold off
-100
-791
-
-%
Jul 12, 2024
BARTLETT & CO. WEALTH MANAGEMENT LLC
unchanged
-
18.00
117
-%
Jul 10, 2024
CWM, LLC
unchanged
-
-
-
-%
Jul 10, 2024
ALBION FINANCIAL GROUP /UT
unchanged
-
39.00
249
-%
Jul 08, 2024
THOMPSON INVESTMENT MANAGEMENT, INC.
unchanged
-
1,870
12,156
-%
Jun 21, 2024
Cape Investment Advisory, Inc.
sold off
-100
-1,176
-
-%
May 24, 2024
Northwest Bank & Trust Co
unchanged
-
-425
123
-%
May 15, 2024
MILLENNIUM MANAGEMENT LLC
added
33.11
-36,293
18,379
-%
May 15, 2024
ARMISTICE CAPITAL, LLC
new
-
1,827,540
1,827,540
0.02%

1–10 of 41

Are Funds Buying or Selling AXDX?

Are funds buying AXDX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own AXDX
No. of Funds

Unveiling Accelerate Diagnostics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
May 23, 2024
schuler jack w
45.4%
11,234,745
SC 13D/A
Mar 05, 2024
griffin asset management, inc.
8.4%
1,219,724
SC 13G
Jun 20, 2023
schuler jack w
40.6%
58,012,207
SC 13D/A
Jun 20, 2023
indaba capital management, l.p.
9.9%
15,972,241
SC 13D
Jun 08, 2023
schuler jack w
19.99%
20,260,952
SC 13D/A
Feb 24, 2022
feinberg larry n
4.97%
3,257,503
SC 13G/A
Feb 11, 2022
feinberg larry n
5.53%
3,627,549
SC 13G/A
Dec 03, 2021
schuler jack w
26.4%
18,409,240
SC 13D/A
Oct 05, 2021
schuler jack w
25.7%
17,186,959
SC 13D/A
Feb 16, 2021
feinberg larry n
6.67%
3,806,139
SC 13G/A

Recent SEC filings of Accelerate Diagnostics Inc

View All Filings
Date Filed Form Type Document
Jul 01, 2024
4
Insider Trading
Jul 01, 2024
4
Insider Trading
Jul 01, 2024
4
Insider Trading
Jun 05, 2024
8-K
Current Report
Jun 03, 2024
4
Insider Trading
Jun 03, 2024
8-K
Current Report
May 31, 2024
SD
SD
May 30, 2024
4
Insider Trading
May 30, 2024
8-K
Current Report
May 30, 2024
4
Insider Trading

Peers (Alternatives to Accelerate Diagnostics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
177.6B
40.3B
-1.87% -8.75%
31.54
4.4
-2.84% -3.00%
66.7B
19.7B
-1.27% -12.39%
50.03
3.38
4.82% -17.56%
18.9B
3.9B
3.77% -24.06%
40.93
4.83
5.72% 46.72%
18.0B
14.9B
4.77% -28.30%
6.8
1.21
2.98% 207.68%
MID-CAP
9.7B
3.5B
-0.49% 22.32%
30.92
2.73
6.16% 35.06%
9.0B
12.4B
3.05% -11.95%
23.22
0.73
-0.93% -18.83%
8.5B
2.6B
2.70% -25.47%
-26.25
3.25
-6.25% -68.58%
5.5B
3.9B
2.69% -35.08%
-57.29
1.39
0.23% 90.80%
3.5B
387.1M
0.41% 33.97%
-217.07
8.93
30.82% 65.57%
2.2B
6.6B
-1.26% -22.56%
11.83
0.33
1.50% -10.09%
SMALL-CAP
1.4B
3.2B
-5.25% -24.25%
-2.04
0.44
7.94% -1695.32%
408.8M
169.3M
6.32% 8.33%
-5.32
2.42
7.49% -244.90%
287.6M
324.0M
27.08% -17.85%
-1.5
0.89
-3.19% -337.41%
46.8M
50.5M
-0.74% -76.96%
-2.05
0.93
14.25% -10.06%
5.7M
3.5M
-39.71% -89.21%
-0.47
1.62
-0.62% -1.48%

Accelerate Diagnostics Inc News

Latest updates
Defense World17 Jul 202405:38 am

Accelerate Diagnostics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-3.5%2,921,0003,027,0003,299,0002,921,0002,812,0002,973,0002,960,0003,861,0002,958,0003,344,0003,122,0002,798,0002,518,0003,110,0003,588,0002,125,0002,342,0003,470,0002,271,0001,806,0001,750,000
Gross Profit14.2%723,000633,000107,000799,0001,011,000842,000579,0001,080,000802,000-3,317,000986,0001,053,000897,0001,149,0001,301,000954,0001,055,0001,513,0001,154,000899,000834,000
Costs and Expenses-4.3%10,879,00011,363,50014,757,00013,384,00017,073,00014,801,50015,540,00019,069,00016,697,00016,094,00015,518,00018,643,00020,924,00016,229,50016,466,00016,679,00018,785,00019,783,00018,807,00018,986,00019,656,000
  S&GA Expenses-1.5%5,706,0005,794,0007,761,0007,564,00010,105,0008,771,5008,255,00011,493,00010,673,00011,491,50010,806,00012,910,00014,029,00011,165,00011,465,00011,332,00012,943,00013,583,50012,743,00012,837,00012,723,000
  R&D Expenses-7.1%5,173,0005,569,5006,996,0005,820,0006,968,0006,030,0007,285,0007,576,0006,024,0004,602,5004,712,0005,733,0006,895,0005,064,5005,001,0005,347,0005,842,0006,199,5006,064,0006,149,0006,933,000
EBITDA Margin5.4%-4.50-4.76-4.98-6.55-4.89-4.47-5.28-4.42-4.80-5.67-5.71-6.32-6.49--------
Interest Expenses-91.8%10,000122,000----351,500713,0001,506,000-4,095,0004,211,0004,177,0004,090,000-7,251,5003,955,0003,835,0003,749,0003,671,0003,598,0003,528,0003,459,000
Income Taxes-100.0%-556,500131,000156,000--77,000---45,000---5,000----110,500-239,00017,000221,000
Earnings Before Taxes-14.4%-14,230,000-12,434,5001,041,000-32,579,000-16,795,000-14,686,000-15,896,000-18,523,000-13,465,000-22,758,000-8,986,000-21,674,000-24,239,000-18,907,000-18,757,000-19,230,000-21,309,000-21,445,500-20,673,000-20,798,000-21,500,000
EBT Margin5.1%-4.78-5.04-5.25-6.85-5.23-4.91-5.38-4.80-5.47-6.59-6.39-6.96-7.15--------
Net Income-9.5%-14,230,000-12,998,000910,000-32,735,000-16,795,000-14,609,000-15,896,000-18,523,000-13,465,000-22,803,000-8,986,000-21,674,000-24,239,000-18,912,000-18,757,000-19,230,000-21,309,000-21,335,000-20,434,000-20,815,000-21,721,000
Net Income Margin5.0%-4.85-5.11-5.27-6.86-5.22-4.90-5.39-4.80-5.48-6.59-6.39-6.96-7.15--------
Free Cashflow-9.0%-8,452,000-7,755,000-8,314,266-10,906,266-13,440,266-9,623,266-13,646,266-13,072,266-12,679,266-12,020,266-12,521,266-9,626,266-13,448,266--------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-2.1%31.0031.0039.0050.0051.0065.0076.0059.0070.0083.0081.0094.0093.0093.00104115120134147159172
  Current Assets-1.4%24.0024.0032.0042.0043.0056.0066.0048.0061.0073.0072.0084.0082.0082.0092.00103107122134150164
    Cash Equivalents20.3%15.0012.0020.0029.0029.0035.0039.005.0014.0040.0036.0045.0043.0036.0027.0047.0039.0061.0093.0087.0075.00
  Inventory-1.8%3.003.004.005.005.005.005.005.006.005.0010.0010.0010.009.009.009.009.008.008.008.009.00
  Net PPE33.8%3.002.003.003.003.003.004.004.005.005.005.006.006.006.007.008.009.008.009.008.007.00
Liabilities10.2%57.0051.0074.0089.0090.0087.0086.00121126118121164159156154152143142137133129
  Current Liabilities34.0%16.0012.0038.0054.0068.0067.0066.0067.001147.008.009.007.007.007.0010.007.008.006.008.006.00
  Long Term Debt--------50.009.00108110147144141138135133130127125122
    LT Debt, Current0%1.001.001.001.0057.0056.0056.0056.00106-0.001.001.001.001.002.00-----
    LT Debt, Non Current--------50.009.00108110147144141138135133130127125122
Shareholder's Equity-29.6%-25.78-19.89--0.000.00-0.00-0.00-514-475-0.000.00-10.0026.0043.00
  Retained Earnings-2.1%-683-668-655-656-624-607-592-576-558-570-547-538-517-492-474-455-436-414-393-372-352
  Additional Paid-In Capital1.2%703695666664631630628560547581553514496475469463458452449444440
Shares Outstanding49.7%22.0015.0015.0014.0010.0010.009.008.007.006.006.006.006.00--------
Float----61.00---53.00---320---480---714-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-9.0%-8,452-7,755-8,253-10,821-13,367-9,550-13,573-12,999-12,606-11,947-12,448-9,553-13,375-10,343-12,656-9,798-17,597-13,865-17,367-14,057-19,505
  Share Based Compensation-4.9%1,2971,3641,8151,6535552,4461,2293,9712,9792,9893,6296,5908,8394,1734,6763,4164,1993,2093,1312,8813,397
Cashflow From Investing-366.4%-513-110-3549158,2095,84215,7884,428-13,641-2,7502,789-2578,52217,852-9,93811,048-5,356-18,65321,29425,37124,799
Cashflow From Financing10590.7%11,439107-8179,806-77.00-12632,036-35777.0018,89183011,65011,8551,3402,2556,6091,4295811,6228043,816
  Buy Backs----------20,2943.00----------
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

AXDX Income Statement

2024-03-31
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
shares in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Net sales$ 2,921,000$ 2,812,000
Cost of sales2,198,0001,801,000
Gross profit723,0001,011,000
Costs and expenses:  
Research and development5,173,0006,968,000
Sales, general and administrative5,706,00010,105,000
Total costs and expenses10,879,00017,073,000
Loss from operations(10,156,000)(16,062,000)
Other income (expense):  
Loss on fair value adjustments(1,216,000)0
Foreign currency exchange gain19,000233,000
Interest income200,000420,000
Other (expense) income, net(627,000)45,000
Total other expense, net(4,074,000)(733,000)
Net loss before income taxes(14,230,000)(16,795,000)
Provision for income taxes00
Net loss$ (14,230,000)$ (16,795,000)
Basic net loss per share (in usd per share)$ (0.74)$ (1.71)
Diluted net loss per share (in usd per share)$ (0.74)$ (1.71)
Basic weighted average shares outstanding (in shares)19,2169,830
Diluted weighted average shares outstanding (in shares)19,2169,830
Other comprehensive loss:  
Net loss$ (14,230,000)$ (16,795,000)
Net unrealized gain on debt securities available-for-sale024,000
Foreign currency translation adjustment(6,000)(255,000)
Comprehensive loss(14,236,000)(17,026,000)
Nonrelated Party  
Other income (expense):  
Interest expense(2,450,000)(418,000)
Related Party  
Other income (expense):  
Interest expense$ 0$ (1,013,000)

AXDX Balance Sheet

2024-03-31
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 14,606$ 12,138
Investments1,1451,081
Trade accounts receivable, net2,2172,622
Inventory3,2493,310
Prepaid expenses1,068380
Purchase obligation put option asset03,419
Other current assets1,8481,516
Total current assets24,13324,466
Property and equipment, net3,1972,389
Finance lease assets, net1,2251,518
Operating lease right of use assets, net9571,177
Other non-current assets1,2101,816
Total assets30,72231,366
Current liabilities:  
Accounts payable5,1084,796
Accrued liabilities3,3513,243
Accrued interest1,014164
Deferred revenue and income, current1,2721,545
Current portion of convertible notes726726
Common warrant liability3,0350
Finance lease, current685583
Operating lease, current940977
Total current liabilities16,13112,034
Finance lease, non-current81262
Operating lease, non-current328570
Deferred income, non-current1,1101,122
Other non-current liabilities1,1971,164
Convertible notes, non-current37,65536,102
Total liabilities56,50251,254
Commitments and contingencies (see Note 14)
Stockholders’ deficit:  
Preferred shares, $0.001 par value; $5,000,000 preferred shares authorized with no shares issued and outstanding on March 31, 2024 and December 31, 202300
Common stock, $0.001 par value; $450,000,000 common shares authorized with 21,811,706 shares issued and outstanding on March 31, 2024 and 14,569,500 shares issued and outstanding on December 31, 20232114
Contributed capital702,971694,634
Treasury stock(45,067)(45,067)
Accumulated deficit(683,087)(668,857)
Accumulated other comprehensive loss(618)(612)
Total stockholders’ deficit(25,780)(19,888)
Total liabilities and stockholders’ deficit$ 30,722$ 31,366
AXDX
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. The company was incorporated in 1982 and is headquartered in Tucson, Arizona.
 CEO
 WEBSITEhttps://acceleratediagnostics.com
 INDUSTRYMedical Instruments & Supplies
 EMPLOYEES179

Accelerate Diagnostics Inc Frequently Asked Questions


What is the ticker symbol for Accelerate Diagnostics Inc? What does AXDX stand for in stocks?

AXDX is the stock ticker symbol of Accelerate Diagnostics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Accelerate Diagnostics Inc (AXDX)?

As of Fri Jul 19 2024, market cap of Accelerate Diagnostics Inc is 24.48 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AXDX stock?

You can check AXDX's fair value in chart for subscribers.

What is the fair value of AXDX stock?

You can check AXDX's fair value in chart for subscribers. The fair value of Accelerate Diagnostics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Accelerate Diagnostics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AXDX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Accelerate Diagnostics Inc a good stock to buy?

The fair value guage provides a quick view whether AXDX is over valued or under valued. Whether Accelerate Diagnostics Inc is cheap or expensive depends on the assumptions which impact Accelerate Diagnostics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AXDX.

What is Accelerate Diagnostics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 19 2024, AXDX's PE ratio (Price to Earnings) is -0.41 and Price to Sales (PS) ratio is 2.01. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AXDX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Accelerate Diagnostics Inc's stock?

In the past 10 years, Accelerate Diagnostics Inc has provided -0.407 (multiply by 100 for percentage) rate of return.